APTA Therapeutics, today announced that it has received notices of allowance for a key patent application in both the United States and Japan, marking a significant milestone in the company’s intellectual property strategy.

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.

APTA Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with regulatory autoantibodies, strengthens its management team.

Click here for the article:

https://thesicktimes.org/2025/07/22/berlin-cures-failed-long-covid-clinical-trial-yields-lessons-on-study-design/

The newly founded APTA Therapeutics has acquired assets from Berlin Cures and intends to continue clinical development of rovunaptabin, formally BC 007.